Hemophagocytic Lymphohistiocytosis Due to Acute Myeloid Leukemia Relapse: A Very Unusual AssociationMaya Belhadj1,2, Barbara Burroni1,3, Felipe Suarez1,4, Frederic Pene1,5, Nicolas Chapuis1,6, Sylvain Pilorge1,2, Lise Willems1,2, Patricia Franchi1,2, Bénédicte Deau1,2, Didier Bouscary1,2, Jerome Tamburini1,2* and Marielle Le Goff1,2
- *Corresponding Author:
- Jerome Tamburini
Université Paris Descartes
Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France
E-mail: [email protected]
Received date: November 25, 2015 Accepted date: December 15 2015 Published date: December 18, 2015
Citation: Maya Belhadj, Barbara Burroni, Felipe Suarez, Frederic Pene, Nicolas Chapuis, et al. (2015) Hemophagocytic Lymphohistiocytosis Due to Acute Myeloid Leukemia Relapse: A Very Unusual Association. J Leuk 3:198. doi:10.4172/2329-6917.1000198
Copyright: © 2015 Maya B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Hemophagocytic lymphohistiocytosis (HLH) diagnosed in the course of acute myeloid leukemia (AML) is generally triggered by treatment-induced infections. AML-induced HLH is a very rare situation for which no diagnostic or therapeutic guidelines are available. We report the occurrence of HLH in an AML5 post-transplant relapse. In our case, the absence of detectable pathogen and the parallel evolution between HLH and leukemia burden suggested a direct link between AML and HLH. We suggest that the diagnostic of AML-related HLH should be promptly considered in front of unexplained fever, cytopenia, liver dysfunction or neurological symptoms as therapeutic intervention is urgent in this life-threatening situation.